CDX2 antibody (AA 1-30)

Catalog No. ABIN3030336

Product Details anti-CDX2 Antibody

Target: CDX2 (Caudal Type Homeobox 2 (CDX2))

Binding Specificity: AA 1-30

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This CDX2 antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Cross-Reactivity (Details): Expected species reactivity: Mouse

Purification: Purified

Immunogen: A portion of amino acids 1-30 from the human protein was used as the immunogen for this CDX2 antibody.

Isotype: Ig Fraction

Application Details

Application Notes: Titration of the CDX2 antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 1:1000,IHC (Paraffin): 1:50-1:100

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: In 1X PBS, pH 7.4, with 0.09 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Aliquot the CDX2 antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

Target Details for CDX2

Target: CDX2 (Caudal Type Homeobox 2 (CDX2))

Alternative Name: CDX2 (CDX2 Products)

Synonyms: CDX2 antibody, MGC130987 antibody, cdx3-like antibody, CDX-3 antibody, CDX3 antibody, CDX-2 antibody, Cdx-2 antibody, caudal type homeobox 2 antibody, caudal type homeobox 2 L homeolog antibody, caudal type homeo box 2 antibody, CDX2 antibody, cdx2.L antibody, Cdx2 antibody

Background: The caudal type homeo box transcription factors 1 (CDX1) and 2 (CDX2) are candidates for directing intestinal development, differentiation, and maintenance of the intestinal phenotype. CDX1 and CDX2 expression is widely present in the human intestinal and colonic mucosae, but not in the gastric mucosa, suggesting a possible role in the terminal differentiation of the intestine. Increased CDX2 expression is associated with chronic atrophic gastritis. Detectable expression of CDX2 precedes expression of CDX1 during the progression of intestinal metaplasia, thus expression of CDX2 may trigger the initiation and development of intestinal metaplasia. Markedly reduced or absent CDX2 expression was noted by immunohistochemistry in 13 of 15 (87 % ) large cell minimally differentiated carcinomas (LCMDCs), whereas only 1 of the 25 (4 %) differentiated adenocarcinomas (DACs) showed reduced CDX2 expression. Thus, a significant decrease in human CDX1 and/or CDX2 expression may be associated with colorectal tumorigenesis.

UniProt: Q99626

Pathways: Peptide Hormone Metabolism, Stem Cell Maintenance